Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set

被引：0
|
作者：
A Lotery
R Griner
A Ferreira
F Milnes
P Dugel
机构：
[1] Eye Unit,
[2] University Hospital Southampton NHS Foundation Trust,undefined
[3] Clinical and Experimental Sciences,undefined
[4] Faculty of Medicine,undefined
[5] University of Southampton,undefined
[6] QuintilesIMS,undefined
[7] Novartis Pharma AG,undefined
[8] Retinal Consultants of Arizona LTD,undefined
来源：
Eye | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1697 / 1706
页数：9
相关论文
共 50 条
  • [1] Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
    Lotery, A.
    Griner, R.
    Ferreira, A.
    Milnes, F.
    Dugel, P.
    [J]. EYE, 2017, 31 (12) : 1697 - 1706
  • [2] Measuring real-world visual acuity outcomes for ranibizumab and aflibercept in treatment of neovascular age-related macular degeneration (nAMD)
    Karamat, Ayesha
    O'Neill, Charles
    Corradetti, Giulia
    Lindenberg, Sophiana
    Tojjar, Jasaman
    Almidani, Louay
    Do, Giang
    Mauger, Stephanie
    Nittala, Muneeswar
    Chauhan, Devinder
    Sadda, SriniVas
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [3] Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
    Mehta, Hemal
    Kim, Leah N.
    Mathis, Thibaud
    Zalmay, Pardis
    Ghanchi, Faruque
    Amoaku, Winfried M.
    Kodjikian, Laurent
    [J]. CLINICAL OPHTHALMOLOGY, 2020, 14 : 3331 - 3342
  • [4] Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD
    Waldstein, Sebastian M.
    Wright, Jonathan
    Warburton, James
    Margaron, Philippe
    Simader, Christian
    Schmidt-Erfurth, Ursula
    [J]. OPHTHALMOLOGY, 2016, 123 (01) : 60 - 69
  • [5] Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
    Providencia, Joana
    Rodrigues, Tiago M.
    Oliveira, Mariana
    Bernardes, Joao
    Marques, Joao Pedro
    Murta, Joaquim
    Silva, Rufino
    [J]. BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [6] Visual Acuity Outcomes in Neovascular AMD Patients Receiving Series of Three Ranibizumab Injections on Indication
    Vora, A. V.
    Ranchod, T. M.
    Walsh, M. K.
    Shobe, B.
    Harinandan, A.
    Alfares, S.
    Drenser, K. A.
    Hassan, T. S.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [7] Real-world one year outcomes of a switch to aflibercept from ranibizumab in neovascular age related macular degeneration
    Citu, Maria Cristina
    Crosby-Nwaobi, Roxanne R.
    Eleftheriadou, Maria
    Vazquez-Alfageme, Clara
    Nicholson, Luke
    Sivaprasad, Sobha
    Hykin, Philip
    Hamilton, Robin D.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [8] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    Chong, V.
    [J]. EYE, 2016, 30 (02) : 270 - 286
  • [9] Evaluation of contrast sensitivity and other visual function outcomes in neovascular AMD patients following treatment switch to aflibercept from ranibizumab
    Nixon, Don
    Flinn, Nicholas
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [10] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    [J]. Eye, 2016, 30 : 270 - 286
12345